Signos, Inc.
Offers an FDA-cleared AI-powered glucose monitoring system for weight management and metabolic health
$20MGrowth
Role not disclosedGG
GV (Google Ventures)
Activity from announced rounds
Activity in this selectionMay 31, 2026 · AI · May 1, 2026
GV invests in technology and life-science companies, including AI applications, developer tools, cybersecurity, computing infrastructure and healthcare.
Its AI interests span the stack: new computing systems and inference infrastructure, tools for developers, software for professional workflows and applications in drug discovery and patient care. This gives both infrastructure founders and application builders a route to a specialist investment team.
GV developed the design sprint, a five-day process that takes a business question through problem definition, prototyping and customer testing. Its published sprint materials help teams test demand and product decisions before committing to a full launch.
- Rounds participated in
- 5
- Confirmed lead rounds
- — 5 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $2.8B 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionFlick
AI-native filmmaking platform giving creators cinematic control to direct AI-generated films
$6MSeed
Role not disclosedNectar Social
Provides AI infrastructure for modern marketing
$30MSeries A
Role not disclosedRecursive Superintelligence
Develops self-improving AI systems that autonomously enhance their own architecture and training algorithms
$650MSeries A
Role not disclosedIsomorphic Labs
Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas
$2.1BSeries B
Role not disclosed